The next generation of antiviral therapies: After successfully passing an important preclinical development milestone for the lead compound ATR-002 in summer 2017, Atriva Therapeutics GmbH adds a seasoned biopharmaceutical executive, Dr. Christi
A new article has been published in the German publication "Platform Life Sciences" written by Prof. Oliver Planz highlighting the ATRIVA approach:
"Die Virusgrippe „Influenza“ zählt zu den akuten Atemwegserkrankungen (ARE).
Invited keynote lecture on ATRIVAs antiviral MEK inhibitor technology presented at the Annual Meeting of the German Pharmaceutical Society (DPhG)
Atriva scientists were invited to give a keynote lecture on their antiviral MEK inhibitor concept at the Annual Meeting of the German Pharmaceutical Society (DPhG).
The meeting entitled „Novel Therapies for Future Challenges“ was held